These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 30185173)
1. Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis. Men P; Yi Z; Li C; Qu S; Xiong T; Yu X; Zhai S BMC Psychiatry; 2018 Sep; 18(1):286. PubMed ID: 30185173 [TBL] [Abstract][Full Text] [Related]
2. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402 [TBL] [Abstract][Full Text] [Related]
3. Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China. Yi ZM; Men P; Qu S; Li C; Yu X; Zhai S Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):313-320. PubMed ID: 32293194 [TBL] [Abstract][Full Text] [Related]
5. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. Bhowmick S; Hazra A; Ghosh M Aust N Z J Psychiatry; 2010 Mar; 44(3):237-42. PubMed ID: 20050717 [TBL] [Abstract][Full Text] [Related]
6. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Krzystanek M; Krupka-Matuszczyk I Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416 [TBL] [Abstract][Full Text] [Related]
7. Aripiprazole versus other atypical antipsychotics for schizophrenia. Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570 [TBL] [Abstract][Full Text] [Related]
8. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. Smith RC; Leucht S; Davis JM Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237 [TBL] [Abstract][Full Text] [Related]
9. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Mortimer A; Martin S; Lôo H; Peuskens J; Int Clin Psychopharmacol; 2004 Mar; 19(2):63-9. PubMed ID: 15076013 [TBL] [Abstract][Full Text] [Related]
10. Amisulpride: a review of its use in the management of schizophrenia. McKeage K; Plosker GL CNS Drugs; 2004; 18(13):933-56. PubMed ID: 15521794 [TBL] [Abstract][Full Text] [Related]
11. Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis. Law WL; Hui HY; Young WM; You JH Int J Clin Pharmacol Ther; 2007 May; 45(5):264-70. PubMed ID: 17542348 [TBL] [Abstract][Full Text] [Related]
12. Olanzapine: an updated review of its use in the management of schizophrenia. Bhana N; Foster RH; Olney R; Plosker GL Drugs; 2001; 61(1):111-61. PubMed ID: 11217867 [TBL] [Abstract][Full Text] [Related]
13. Quetiapine versus other atypical antipsychotics for schizophrenia. Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315 [TBL] [Abstract][Full Text] [Related]
14. A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. Martin S; Lĵo H; Peuskens J; Thirumalai S; Giudicelli A; Fleurot O; Rein W; Curr Med Res Opin; 2002; 18(6):355-62. PubMed ID: 12442883 [TBL] [Abstract][Full Text] [Related]
15. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Leucht S Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080 [TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness study of olanzapine pamoate: Mirror-image analysis after one year]. Potaufeu J; Langrée B; Drapier D; Burgot G; Marie N Encephale; 2019 Jun; 45(3):232-238. PubMed ID: 30579574 [TBL] [Abstract][Full Text] [Related]
17. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Vanelle JM; Douki S Eur Psychiatry; 2006 Dec; 21(8):523-30. PubMed ID: 17113759 [TBL] [Abstract][Full Text] [Related]
18. Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment. Kruse G; Wong BJ; Duh MS; Lefebvre P; Lafeuille MH; Fastenau JM Pharmacoeconomics; 2015 Oct; 33(10):1049-67. PubMed ID: 25963579 [TBL] [Abstract][Full Text] [Related]
19. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Kahn RS; Winter van Rossum I; Leucht S; McGuire P; Lewis SW; Leboyer M; Arango C; Dazzan P; Drake R; Heres S; Díaz-Caneja CM; Rujescu D; Weiser M; Galderisi S; Glenthøj B; Eijkemans MJC; Fleischhacker WW; Kapur S; Sommer IE; Lancet Psychiatry; 2018 Oct; 5(10):797-807. PubMed ID: 30115598 [TBL] [Abstract][Full Text] [Related]
20. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Swainston Harrison T; Perry CM Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]